Encephalomyelitis - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 40 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Encephalomyelitis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Encephalomyelitis - Pipeline Review, H2 2016', provides an overview of the Encephalomyelitis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Encephalomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Encephalomyelitis
- The report reviews pipeline therapeutics for Encephalomyelitis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Encephalomyelitis therapeutics and enlists all their major and minor projects
- The report assesses Encephalomyelitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Encephalomyelitis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Encephalomyelitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Encephalomyelitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Encephalomyelitis Overview 6
Therapeutics Development 7
Pipeline Products for Encephalomyelitis - Overview 7
Pipeline Products for Encephalomyelitis - Comparative Analysis 8
Encephalomyelitis - Therapeutics under Development by Companies 9
Encephalomyelitis - Therapeutics under Investigation by Universities/Institutes 10
Encephalomyelitis - Pipeline Products Glance 11
Early Stage Products 11
Encephalomyelitis - Products under Development by Companies 12
Encephalomyelitis - Products under Investigation by Universities/Institutes 13
Encephalomyelitis - Companies Involved in Therapeutics Development 14
Bionure Farma, S.L. 14
Biovista Inc. 15
Momenta Pharmaceuticals, Inc. 16
OSE Immunotherapeutics 17
Encephalomyelitis - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 24
Drug Profiles 26
Antibody for Autoimmune Disorders and Inflammation - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
BN-201 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
FR-104 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
JM-4 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
PSA-20 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecule for Chronic Fatigue Syndrome and Myalgic Encephalomyelitis - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
thymulin - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
WEHI-345 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Encephalomyelitis - Dormant Projects 37
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 39
Disclaimer 40

List of Tables

Number of Products under Development for Encephalomyelitis, H2 2016 7
Number of Products under Development for Encephalomyelitis - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Products under Investigation by Universities/Institutes, H2 2016 13
Encephalomyelitis - Pipeline by Bionure Farma, S.L., H2 2016 14
Encephalomyelitis - Pipeline by Biovista Inc., H2 2016 15
Encephalomyelitis - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016 16
Encephalomyelitis - Pipeline by OSE Immunotherapeutics, H2 2016 17
Assessment by Monotherapy Products, H2 2016 18
Number of Products by Stage and Target, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 22
Number of Products by Stage and Route of Administration, H2 2016 23
Number of Products by Stage and Molecule Type, H2 2016 25
Encephalomyelitis - Dormant Projects, H2 2016 37
Encephalomyelitis - Dormant Projects (Contd..1), H2 2016 38